Furyl-nonatetraene derivatives and the pharmaceutically acceptable salts thereof, processes for their preparation, starting compounds used in these processes, and pharmaceutical compositions containing them
申请人:F. HOFFMANN-LA ROCHE & CO.
Aktiengesellschaft
公开号:EP0008665A1
公开(公告)日:1980-03-19
The new furyl-nonatetraene derivatives of the formula
and the pharmaceutically acceptable salts thereof, e.g. (E, E, E, E,) -3,7-dimethyl-9-(2,4,5-trimethyl-3-furyl)- 2,4,6,8- nonatetraenoic acid ethyl ester, are effective in regressing the growth of tumors and chondrosarcoma and they are useful as medicaments for therapy of acne, psoriasis and other dermatological disorders. They may be therefore included in pharmaceutical preparations.
The compounds of the formula may be prepared by a process which comprises
a) reacting a compound of the formula
with a new compound of the formula
or
b) reacting a new compound of the formula
with a compound of the formula
or
The meaning of the substituents see inside the description.
式中的新呋喃基-壬四烯衍生物及其药物可接受盐,例如
及其药学上可接受的盐类,例如(E,E,E,E,E,)-3,7-二甲基-9-(2,4,5-三甲基-3-呋喃基)-2,4,6,8-壬四烯酸乙酯,可有效抑制肿瘤和软骨肉瘤的生长,并可用作治疗痤疮、牛皮癣和其他皮肤病的药物。因此,它们可用于药物制剂中。
式中化合物的制备过程包括
a) 将式化合物
与一种新的式化合物反应
或
b) 将一种新的式化合物
与式化合物反应
或
取代基的含义见说明。